Japan’s medtech startup CureApp gets $14M to help reduce lifestyle diseases globally


Japan’s digital health startup CureApp announced on Monday that it has fundraised 1.5 billion yen (about $14 million) in the latest round. This follows their previous $3.4 million funding from Beyond Next Ventures (BNV), Keio Innovation Initiative (KII), and SBI Investment back in February last year.
In addition to existing investors BNV and KII, participating investors in this round are Itochu Corporation (TSE:8001), Itochu Technology Ventures, Cyberdine (TSE:7779), Dai-ichi Life (TSE:8750), Mitsubishi UFJ Capital, Iwagin Jigyo Souzou Capital, Saison Ventures, Chibagin Capital, and Mizuho Capital.

Read here in Detail : The Bridge

Comments

Post a Comment

Popular posts from this blog

World’s First Medical Device Regulatory Approval of Digital Therapeutic App for Hypertension

Image
World’s First Medical Device Regulatory Approval of Digital Therapeutic App for Hypertension Mental and Behavioral Approaches to Lifestyle Modification 　CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake) was notified by the Ministry of Health, Labour and Welfare on April 26, 2022 that the company had received the medical device regulatory approval of an digital therapeutic app for Hypertension. This marks the first time a standalone software app supporting doctors and patients has received medical device regulatory approval in Japan, and is the first app addressing hypertension to be approved in the world. Preparations are now underway to receive reimbursement and launch the app in 2022. Hypertension  　 　Lifestyle modification is a vitally important part of treating essential hypertension, regardless of blood pressure classification. However, lifestyle modifications are dependent on the patient’s mindset and motivation, and workplace and home environment, and are difficult
Read more

CureApp SC, Digital Therapeutic for Nicotine Addiction: Introducing a New Form of App-based Prescription Treatment Reimbursed in Japan’s Public Healthcare Insurance System

Image
CureApp SC, Digital Therapeutic for Nicotine Addiction: Introducing a New Form of App-based Prescription Treatment Reimbursed in Japan’s Public Healthcare Insurance System -  The Firs t Digital Therapeutic  to Be Covered by Japan’s Public Healthcare Insurance System CureApp, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Kohta Satake) has announced that CureApp SC Nicotine Addiction Treatment App and CO Checker (hereafter, CureApp SC) – a treatment app(digital therapeutic) targeting nicotine addiction – is now covered by Japan’s public healthcare insurance system as of December 1, 2020, following a period of clinical trials and regulatory approval. This marks the first case of a digital therapeutics application being covered by the insurance, as well as the first time that a digital therapeutic in the field of smoking cessation treatments has been covered by a country’s national health insurance system in the world. Patients diagnosed with nicotine addiction at a medical institution are elig
Read more

【Publication information】"Digital Therapeutics will Become a Major Treatment Option in the Future: Kohta Satake, CEO of CureApp."

Image
We are pleased to inform you that our article has been published on Smart Industry News titled "Digital Therapeutics will Become a Major Treatment Option in the Future: Kohta Satake, CEO of CureApp." https://www.smartindustrynews.com/sin-article/digital-therapeutics-will-become-a-major-treatment-option-in-the-future-kohta-satake-ceo-of-cureapp/
Read more